Henlius and Organon revealed results from the P-III trial evaluating the safety, efficacy tolerability and immunogenicity of HLX14 (60mg, SC, Q8M) vs reference candidate denosumab to treat postmenopausal women with osteoporosis at high-risk of fracture
The study achieved the 1EPs of percentage change in BMD at the lumbar spine at wk.52 (D365) and percentage change in area under the effect–time curve of serum type I collagen C-telopeptide (s-CTX) at wk.26 (D183) (AUEC0–26W)
Henlius collaborated with Organon for exclusive commercialization rights to two biosimilar candidates, incl. HLX14 across the US, the EU and Canada excl. China in 2022
Ref: Henlius | Image: Henlius
Related News:- Henlius Reports the First Patient Dosing in P-III (HLX14-002-PMOP301) Trial of HLX14 (biosimilar, denosumab) to Treat Osteoporosis in Postmenopausal Women
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
